Update on the development of lurasidone as a treatment for patients with acute schizophrenia
Lurasidone is a novel benzisothiazole antipsychotic drug for the treatment of schizophrenia. Of the antipsychotic drugs, lurasidone has the highest affinity for the 5-hydroxytryptamine (5-HT)7 receptor. Lurasidone also has high affinities for the dopamine D2, 5HT2A, 5-HT1A and α2C adrenergic recepto...
Main Author: | Yasui-Furukori, Norio |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367402/ |
Similar Items
-
Critical appraisal of lurasidone in the management of schizophrenia
by: Caccia, Silvio, et al.
Published: (2012) -
Clinical potential of lurasidone in the management of schizophrenia
by: Samalin, Ludovic, et al.
Published: (2011) -
Schizophrenia relapse, patient considerations, and potential role of lurasidone
by: Citrome, Leslie
Published: (2016) -
The clinical utility of lurasidone in schizophrenia: patient considerations
by: Harvey, Philip D
Published: (2015) -
Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia
by: Kaneda, Ayako, et al.
Published: (2013)